{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:34:36Z","timestamp":1791477276975,"version":"4.3.4"},"reference-count":34,"publisher":"Elsevier BV","issue":"5","content-domain":{"domain":["journals.elsevierhealth.com","europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.eururo.2013.10.033","type":"journal-article","created":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T16:03:26Z","timestamp":1383321806000},"page":"981-990","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":146,"title":["An Updated Systematic Review and Statistical Comparison of Standardised Mean Outcomes for the Use of Botulinum Toxin in the Management of Lower Urinary Tract Disorders"],"prefix":"10.1016","volume":"65","author":[{"given":"Altaf","family":"Mangera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apostolos","family":"Apostolidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl Eric","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prokar","family":"Dasgupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Giannantoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Roehrborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Novara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Chapple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2013.10.033_bib0005","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.eururo.2011.07.001","article-title":"Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of Botox (onabotulinumtoxinA) and Dysport (abobotulinumtoxinA)","volume":"60","author":"Mangera","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.10.033_bib0010","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0140-6736(04)17670-8","article-title":"External validity of randomised controlled trials: \u201cto whom do the results of this trial apply?\u201d","volume":"365","author":"Rothwell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2013.10.033_bib0015","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2013.10.033_bib0020","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.eururo.2008.09.009","article-title":"Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report","volume":"55","author":"Apostolidis","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.10.033_bib0025","unstructured":"Higgins JPT, Altman DG. Assessing risk of bias in included studies. In Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. The Cochrane Collaboration Web site. http:\/\/www.cochrane.org\/training\/cochrane-handbook. Updated March 2011."},{"key":"10.1016\/j.eururo.2013.10.033_bib0175","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1007\/s00345-012-0984-0","article-title":"An exploratory, placebo-controlled, dose-response study of the efficacy and safety of onabotulinumtoxinA in spinal cord injury patients with urinary incontinence due to neurogenic detrusor overactivity","volume":"31","author":"Apostolidis","year":"2013","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2013.10.033_bib0180","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/nau.22395","article-title":"The therapeutic effects of repeated detrusor injections between 200 or 300 units of onabotulinumtoxinA in chronic spinal cord injured patients","volume":"33","author":"Chen","year":"2014","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2013.10.033_bib0040","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.eururo.2011.07.002","article-title":"Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial","volume":"60","author":"Cruz","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.10.033_bib0045","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.juro.2012.01.125","article-title":"Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity","volume":"187","author":"Ginsberg","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.10.033_bib0050","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1016\/j.juro.2011.02.004","article-title":"Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial","volume":"185","author":"Herschorn","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.10.033_bib0055","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4103\/0974-7796.82170","article-title":"Prospective randomized trial of 100u vs 200u Botox in the treatment of idiopathic overactive bladder","volume":"3","author":"Altaweel","year":"2011","journal-title":"Urol Ann"},{"key":"10.1016\/j.eururo.2013.10.033_bib0060","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.eururo.2013.04.001","article-title":"OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial","volume":"64","author":"Chapple","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.10.033_bib0065","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.eururo.2011.10.028","article-title":"Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study","volume":"61","author":"Denys","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.10.033_bib0070","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.juro.2012.12.022","article-title":"OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial","volume":"189","author":"Nitti","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.10.033_bib0075","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/1471-0528.12069","article-title":"Validation of the Patient Global Impression scales for use in detrusor overactivity: secondary analysis of the RELAX study","volume":"120","author":"Tincello","year":"2013","journal-title":"BJOG"},{"key":"10.1016\/j.eururo.2013.10.033_bib0080","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.eururo.2012.10.005","article-title":"A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia","volume":"63","author":"Marberger","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.10.033_bib0085","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1464-410X.2009.08466.x","article-title":"Comparing two types of botulinum-A toxin detrusor injections in patients with severe neurogenic detrusor overactivity: a case-control study","volume":"104","author":"Grosse","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2013.10.033_bib0090","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.juro.2010.08.021","article-title":"Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial","volume":"184","author":"Dmochowski","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.10.033_bib0095","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1208872","article-title":"Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence","volume":"367","author":"Visco","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2013.10.033_bib0100","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/nau.21054","article-title":"Bladder base\/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics","volume":"30","author":"Kuo","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2013.10.033_bib0105","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.eururo.2011.10.043","article-title":"Prospective randomised controlled trial comparing trigone-sparing versus trigone-including intradetrusor injection of abobotulinumtoxinA for refractory idiopathic detrusor overactivity","volume":"61","author":"Manecksha","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.10.033_bib0110","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.juro.2007.05.136","article-title":"Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity","volume":"178","author":"Kuo","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.10.033_bib0115","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1136\/jnnp.2004.045765","article-title":"Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients","volume":"76","author":"Gallien","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.eururo.2013.10.033_bib0120","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0090-4295(03)00477-1","article-title":"Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study","volume":"62","author":"Maria","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2013.10.033_bib0125","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/j.1464-410X.2006.06479.x","article-title":"Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia","volume":"98","author":"Chuang","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2013.10.033_bib0130","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.juro.2011.04.062","article-title":"Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia: a phase II randomized clinical trial","volume":"186","author":"Crawford","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.10.033_bib0135","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.eururo.2007.08.050","article-title":"Intraprostatic botulinum toxin type a injection in patients unfit for surgery presenting with refractory urinary retention and benign prostatic enlargement. Effect on prostate volume and micturition resumption","volume":"53","author":"Silva","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.10.033_bib0140","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/nau.20946","article-title":"A pilot study of botulinum toxin for interstitial cystitis\/painful bladder syndrome","volume":"30","author":"Gottsch","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2013.10.033_bib0145","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1464-410X.2009.08495.x","article-title":"Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis\/painful bladder syndrome","volume":"104","author":"Kuo","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2013.10.033_bib0150","doi-asserted-by":"crossref","first-page":"E15","DOI":"10.36076\/ppj.2013\/16\/E15","article-title":"Repeated onabotulinumtoxin-a injections provide better results than single injection in treatment of painful bladder syndrome","volume":"16","author":"Kuo","year":"2013","journal-title":"Pain Physician"},{"key":"10.1016\/j.eururo.2013.10.033_bib0155","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.eururo.2011.07.034","article-title":"Should we stop using botulinum neurotoxin type a in patients with neurogenic detrusor overactivity after development of secondary resistance?","volume":"60","author":"Pistolesi","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.10.033_bib0160","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1016\/j.juro.2007.08.032","article-title":"Botulinum-A toxin: solo treatment for neuropathic noncompliant bladder","volume":"178","author":"Neel","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.10.033_bib0165","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1016\/j.juro.2011.01.037","article-title":"A simplified technique for botulinum toxin injections in children with neurogenic bladder","volume":"185","author":"Pascali","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.10.033_bib0170","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.urology.2009.09.087","article-title":"Intravesical injections of botulinum toxin type A for management of neuropathic bladder: a comparison of two methods","volume":"76","author":"Safari","year":"2010","journal-title":"Urology"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283813011093?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283813011093?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,19]],"date-time":"2024-05-19T05:38:35Z","timestamp":1716097115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283813011093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0302283813011093"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2013.10.033","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An Updated Systematic Review and Statistical Comparison of Standardised Mean Outcomes for the Use of Botulinum Toxin in the Management of Lower Urinary Tract Disorders","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2013.10.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}